

Save the date: September 30, Nuclear Radiology Rounds at LUMC:

LUMC Top Research Seminar
**“Precision medicine - choosing the right treatment at
the right time by doing the right test -”**

Programme

- 16:00 – 17:00 **Coffee and Cake at the Paleijhs (route 537): to give Residents and PhD Candidates at LUMC and all others who are interested the opportunity to Meet and Greet the expert**
- 17:00 – 17:05 **Lecture Hall 5 (route 558): Welcome by Prof. Pancras Hogendoorn, Dean**
- 17:05 – 18:00 **Lecture Prof. Rodney Hicks: Precision medicine - choosing the right treatment at the right time by doing the right test -**
- 18:00 – 19:00 **Typical Dutch Buffet at the Paleijhs, open for all attendees of the Nuclear Radiology Rounds**
- 19:00 – 21:00 **Nuclear Radiology Rounds at Lecture Hall 3 (route 766):**
- **Welcome by Prof. Lioe-Fee de Geus-Oei**
 - **Stop doing therapeutic lymph node dissections? Prof. Jos van der Hage**
 - **Role of imaging in the Dutch Melanoma Guidelines. Eidrees Ghariq, Resident in Nuclear Radiology**
 - **Interesting cases demonstrated by Susan Meijer, Resident in Nuclear Radiology**
 - **Imaging of melanoma, including immunotherapy monitoring. Prof. Rodney Hicks**



Professor Rodney Hicks, MB BS (Hons), MD, FRACP, FAHMS

Director, Centre for Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre
Professorial Fellow, the Sir Peter MacCallum Department of Oncology, the Department of Medicine and the Department of Radiology, the University of Melbourne
Head, Molecular Imaging and Targeted Therapeutic Laboratory, the Sir Peter MacCallum Department of Oncology
Co-Chair, Neuroendocrine Service
NHMRC Practitioner Fellow

We are delighted to announce that the Godfather of Nuclear Medicine and Molecular Imaging, Professor Rodney Hicks, will be visiting the LUMC on invitation of the department of Radiology,

residency programme on Nuclear Radiology at LUMC/Alrijne Hospital, the profile areas CPT and Biomedical Imaging and the Executive Board of LUMC.

Professor Rodney Hicks is a Professorial Fellow of the University of Melbourne and Director of the Centre for Molecular Imaging and Therapeutic Nuclear Medicine at the Peter MacCallum Cancer Centre in Melbourne, Australia. Peter Mac installed the first PET/CT outside Europe and North America in 2001. The PET facility, founded by him in 1996, now has 4 PET/CT devices and performs over 9,000 scans per year. He has pioneered the use of PET and PET/CT in the assessment of cancer and has introduced a number of novel PET tracers. His group established the first pre-clinical PET imaging facility in Australia in 2002 and has a strong focus on translational research, genomics of rare cancers, and drug development. He is actively involved in the therapeutic nuclear medicine, especially for the treatment of neuroendocrine tumours, having first established peptide receptor radionuclide therapy (PRRT) in Australia in 1996. The Neuroendocrine Service, of which he is Co-Chair, was recently certified as a European Neuroendocrine Tumour Society Centre of Excellence, the first to be granted beyond Europe. His group has been active in the clinical development of prostate cancer theranostics. He has published 500 peer-reviewed articles and more than 20 book chapters. He holds numerous national and international research grants and is Editor-in-Chief of *Cancer Imaging* and International Associate Editor of *The Journal of Nuclear Medicine* as well as serving on 6 other editorial boards including *Endocrine-Related Cancer*. He received a prestigious National Health and Medical Research Council Program Grant in 2013 and NHMRC Practitioner Fellowship in 2015. He was also inducted as a Fellow of the Australian Academy of Health and Medical Science in 2015. He has previously been the Convener of the Theranostics World Congress in 2016 and the Asia-Pacific Neuroendocrine Society Meeting in 2018 and serves on the Scientific Advisory Board of ENETS and as an Honorary Director of the Unicorn Foundation, which supports patients with neuroendocrine neoplasia through advocacy and research funding. He is the recipient of the 2019 International Cancer Imaging Society Gold Medal.